XSHG
603669
Market cap646mUSD
Jul 10, Last price
6.18CNY
1D
0.32%
1Q
33.19%
Jan 2017
-43.55%
IPO
-8.53%
Name
Lionco Pharmaceutical Group Co Ltd
Chart & Performance
P/E
—
P/S
13.67
EPS
—
Div Yield, %
—
Shrs. gr., 5y
-1.59%
Rev. gr., 5y
-20.29%
Revenues
322m
-15.18%
Net income
-193m
L+47.78%
CFO
-132m
L+18.82%
Dividend
Jul 05, 20220.1 CNY/sh
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Lionco Pharmaceutical Group Co., Ltd., in collaboration with its various subsidiaries, actively participates in the entire lifecycle of pharmaceutical products within China, from initial research and development to manufacturing and sales. The company boasts a comprehensive portfolio of therapeutic solutions, encompassing medications for nutritional support, antimicrobial and antiviral treatments, digestive disorders, cardiovascular health, detoxification, and anti-tumor therapies, alongside other specialized products. Furthermore, it maintains dedicated research institutes that focus specifically on the advancement of chemical, natural, and biological drugs. Established in 2003, Lionco Pharmaceutical Group Co., Ltd. is headquartered in Shannan, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||